Asset Details
Do you wish to reserve the book?
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
Do you wish to request the book?
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
2021
Overview
Posttransplant smooth muscle tumors (PTSMTs) are rare Epstein–Barr virus (EBV)-associated neoplasms, mostly occurring after solid organ transplantation. Current therapeutic strategies include surgery and reduction of immunosuppressive medication. We describe for the first time a novel treatment approach for PTSMT by adoptive cell transfer (ACT) of EBV-specific T cells to a 20-year-old patient with a medical history of cardiac transplantation, posttransplant lymphoproliferative disease, and multilocular PTSMT. During ACT, mild cytokine release syndrome occurred, while no unexpected safety signals were recorded. We observed in vivo expansion of EBV-specific T cells and reduction of EBV viremia. Best response was stable disease after 4 months with reduction of EBV viremia and normalization of lactate dehydrogenase levels. ACT with EBV-specific T cells may be a safe and efficacious therapeutic option for PTSMT that warrants further exploration.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Adoptive Transfer - adverse effects
/ alloCELL
/ Allogeneic Cells - immunology
/ Antigens
/ Biopsy
/ Blood
/ Epstein-Barr Virus Infections - complications
/ Epstein-Barr Virus Infections - therapy
/ Epstein-Barr Virus Infections - virology
/ Female
/ Heart
/ Heart Transplantation - adverse effects
/ Herpesvirus 4, Human - immunology
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Immunoproliferative diseases
/ Kinases
/ Lymphoma
/ Lymphoproliferative Disorders - etiology
/ Patients
/ posttransplant smooth muscle tumors
/ PTSMT
/ Smooth Muscle Tumor - complications
/ Smooth Muscle Tumor - etiology
/ Smooth Muscle Tumor - therapy
/ Surgery
/ Tumors
/ Viremia
